CN111757871A - 一种Caspase抑制剂的结晶 - Google Patents
一种Caspase抑制剂的结晶 Download PDFInfo
- Publication number
- CN111757871A CN111757871A CN201980016202.6A CN201980016202A CN111757871A CN 111757871 A CN111757871 A CN 111757871A CN 201980016202 A CN201980016202 A CN 201980016202A CN 111757871 A CN111757871 A CN 111757871A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- crystalline
- ray powder
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请涉及一种caspase抑制剂的结晶,更具体而言涉及(S)‑3‑((S)‑2‑(5‑(2‑氯苯基)异噁唑‑3‑甲酰胺基)丙酰胺基)‑4‑氧代‑5‑(2,3,5,6‑四氟苯氧基)戊酸的结晶,其制备方法、其结晶组合物、药物组合物及其用途。本申请式Ⅰ‑A化合物的结晶稳定性高、吸湿性小,在物理性质、安全性及代谢稳定性方面具备优势,有较高的成药价值。
Description
PCT国内申请,说明书已公开。
Claims (32)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810206043 | 2018-03-13 | ||
CN2018102060433 | 2018-03-13 | ||
CN2018108035810 | 2018-07-20 | ||
CN201810803581 | 2018-07-20 | ||
PCT/CN2019/077939 WO2019174589A1 (zh) | 2018-03-13 | 2019-03-13 | 一种Caspase抑制剂的结晶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111757871A true CN111757871A (zh) | 2020-10-09 |
CN111757871B CN111757871B (zh) | 2022-04-12 |
Family
ID=67908560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980016202.6A Active CN111757871B (zh) | 2018-03-13 | 2019-03-13 | 一种Caspase抑制剂的结晶 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11091450B2 (zh) |
EP (1) | EP3766873A4 (zh) |
CN (1) | CN111757871B (zh) |
AU (1) | AU2019233195A1 (zh) |
CA (1) | CA3093728A1 (zh) |
WO (1) | WO2019174589A1 (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1313846A (zh) * | 1998-07-02 | 2001-09-19 | 伊邓药品公司 | 作为ICE/ced-3族半胱氨酸蛋白酶抑制剂的C端修饰的草氨酰二肽 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
ATE295177T1 (de) * | 1998-03-16 | 2005-05-15 | Cytovia Inc | Dipeptid kaspase inhibitoren und deren verwendung |
WO2017053864A1 (en) * | 2015-09-23 | 2017-03-30 | Intracellular Technologies, Llc | Cysteine protease inhibitors |
US10981860B2 (en) * | 2016-05-11 | 2021-04-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof |
TWI764977B (zh) | 2017-01-23 | 2022-05-21 | 大陸商正大天晴藥業集團股份有限公司 | 作爲caspase抑制劑的聯環化合物、含有其的藥物組合物及其應用 |
-
2019
- 2019-03-13 AU AU2019233195A patent/AU2019233195A1/en not_active Abandoned
- 2019-03-13 CN CN201980016202.6A patent/CN111757871B/zh active Active
- 2019-03-13 EP EP19768641.3A patent/EP3766873A4/en not_active Withdrawn
- 2019-03-13 WO PCT/CN2019/077939 patent/WO2019174589A1/zh unknown
- 2019-03-13 CA CA3093728A patent/CA3093728A1/en active Pending
- 2019-03-13 US US16/977,761 patent/US11091450B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1313846A (zh) * | 1998-07-02 | 2001-09-19 | 伊邓药品公司 | 作为ICE/ced-3族半胱氨酸蛋白酶抑制剂的C端修饰的草氨酰二肽 |
Also Published As
Publication number | Publication date |
---|---|
US20210002235A1 (en) | 2021-01-07 |
EP3766873A4 (en) | 2021-12-15 |
US11091450B2 (en) | 2021-08-17 |
WO2019174589A1 (zh) | 2019-09-19 |
CA3093728A1 (en) | 2019-09-19 |
CN111757871B (zh) | 2022-04-12 |
EP3766873A1 (en) | 2021-01-20 |
AU2019233195A1 (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2386974T3 (es) | Formas cristalinas de la 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida | |
RU2711077C9 (ru) | Соли ингибитора киназы рецептора эпидермального фактора роста | |
RU2464270C2 (ru) | Кристаллические формы сольватированного илапразола | |
CN110494423A (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
KR20210029165A (ko) | 비아릴에테르형 퀴나졸린 유도체 | |
ES2463681T3 (es) | Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6-oxopirimidin-1 (6H)-il]-N-(2-hidroxietil)-4-metilbenzamida | |
CN111757871B (zh) | 一种Caspase抑制剂的结晶 | |
WO2023193563A1 (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
JP2014514274A (ja) | マキサカルシトールの多形およびマキサカルシトールの調製方法 | |
CN116120239A (zh) | 芳香六元环并咪唑类衍生物及其制备方法和应用 | |
EP4083040A1 (en) | Irak4 inhibitor crystal and preparation method therefor | |
CN111132983B (zh) | 一种异喹啉磺酰衍生物的晶型及其制备方法 | |
CN110869382B (zh) | 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途 | |
US7655800B2 (en) | Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses | |
JP2021533111A (ja) | Lta4h阻害剤の結晶形態 | |
CN111484505B (zh) | 一种双环RORγ抑制剂的盐酸盐结晶型 | |
EP4324829A1 (en) | Sulfate of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-n-(tetrahydro-2h-pyran-4-yl)-1h-indole-7-amine, and novel crystal form thereof | |
CN109516957A (zh) | Nl-101多晶型及其制备方法 | |
RU2808992C2 (ru) | Кристаллические формы ингибитора lta4h | |
US20220177463A1 (en) | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof | |
JP5077232B2 (ja) | ベンゾオキサジアゾール誘導体の結晶 | |
ES2348630T3 (es) | Polimorfos de tetomilast. | |
EP1881829A2 (en) | Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses | |
BR112018004596B1 (pt) | Formas sólidas de um sal, seus usos e métodos de preparo, forma sólida de dosagem oral, método de inibição de pim quinase, composição farmacêutica e método de preparo de um sal | |
CN118401513A (zh) | 他伐帕敦的晶型及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |